New presentation with CEO Jenny Sundqvist providing complementary information on the phase III program CONCLUDE with cobitolimod
Get to know interview with CEO Jenny Sundqvist
Our mission is to significantly improve
the lives of patients suffering from
immunological disorders by providing
effective and safe drugs for diseases
with high unmet medical needs.
InDex Pharmaceuticals is developing cobitolimod for the treatment of moderate to severe ulcerative colitis
Capital Markets Day 2022
-
InDex Pharmaceuticals announces positive results from a pharmacokinetic (PK) study with cobitolimod
March 15, 2023 Non Regulatory
-
InDex Pharmaceuticals to attend the ECCO 2023 congress
February 27, 2023 Non Regulatory
InDex Pharmaceuticals published its year-end report for 2022 on February 23 2023 at 08:00 a.m. CET.
-
Annual Report 2022
-
Presentation at Redeye Investor Forum Göteborg
-
Interim Report Q1 2023
Our phase III program CONCLUDE
Have a look at InDex’s corporate presentation
InDex Pharmaceuticals is developing cobitolimod for treatment of moderate to severe left-sided ulcerative colitis
Proud partner of:
